New Delhi, Feb. 9 -- Denmark-based pharmaceutical giant, Novo Nordisk, stock surged more than 8% during the intraday trading session on Monday, 9 February 2026, after rival healthcare firm Hims & Hers withdrew its knockoff weight-loss drug from the market amid US Food and Drug Administration (FDA) scrutiny.

Novo Nordisk stock jumped 8.6% to 321 Danish Krone (kr) during the trading session on Monday, compared to 295.50 kr at the previous stock market close, according to MarketWatch data.

Online medicine provider, Hims & Hers, was selling a knockoff version of the popular weight-loss drug Wegovy, which is manufactured by Danish pharma giant Novo Nordisk.

This move comes after the US FDA, on 6 February 2026, announced that the regulator i...